| Literature DB >> 24367595 |
Pengfei He1, Qi Han1, Jiajia Liu1, Dongjuan Liu1, Xin Zhao1, Ting Hu1, Lu Jiang1, Hongxia Dan1, Xin Zeng1, Jing Li1, Jiayi Wang2, Qianming Chen1.
Abstract
BACKGROUND: The possible association between HIF-1α C1772T polymorphism and cancer risk has been studied extensively. However, the results were controversial. In order to get a more precise conclusion of this association, a meta-analysis was performed.Entities:
Mesh:
Substances:
Year: 2013 PMID: 24367595 PMCID: PMC3867430 DOI: 10.1371/journal.pone.0083441
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Flow chart for the process of selecting associated publications.
Characteristics of populations and cancer types of the studies included in the meta-analysis.
| Author | Year | Country | Ethnicity | Cancer site | Case-control | Gender | Source ofcontrol | Genotypingmethod | HWE |
|---|---|---|---|---|---|---|---|---|---|
| Ribeiro AL | 2013 | Portugal | Caucasian | Breast cancer | 96/74 | Female | HB | PCR–RFLP | 0 |
| Alves LR | 2012 | Brazil | Brazilian | Oral squamous cell carcinoma | 88/40 | Mixed | PB | PCR–RFLP | 0 |
| Zagouri F | 2012 | Greece | Caucasian | Breast cancer | 113/124 | Female | PB | PCR–RFLP | 0.41 |
| Li P | 2012 | China | Asian | Prostate cancer | 662/716 | Male | PB | TaqMan | 0.27 |
| Mera-Menendez F | 2012 | Spain | Caucasian | Glottic cancer | 121/154 | Mixed | PB | PCR–RFLP | 0.01 |
| Ruiz-Tovar J | 2012 | Spain | Caucasian | Pancreatic cancer | 59/159 | Mixed | PB | PCR-RFLP | 0.01 |
| Kuo WH | 2012 | China | Asian | Non-small-cell lung cancer | 285/300 | Mixed | PB | PCR–RFLP | 0.13 |
| Qin C | 2012 | China | Asian | Renal cell carcinoma | 620/623 | Mixed | PB | TaqMan | 0.22 |
| Wang X | 2011 | China | Asian | Pancreatic cancer | 263/271 | Mixed | PB | PCR-SSCP | 0.35 |
| Putra AC | 2011 | Japan | Asian | Lung cancer | 83/110 | Mixed | PB | PCR-SSCP | 0.55 |
| Kim YH | 2011 | Korea | Asian | Cervical cancer | 199/215 | Female | PB | PCR-RFLP | 0.32 |
| Xu G | 2011 | China | Asian | Glioma | 150/150 | Mixed | HB | PCR-RFLP | 0.35 |
| Chai D | 2010 | China | Asian | Cervical cancer | 97/117 | Female | HB | PCR-RFLP | 0.52 |
| Shieh TM | 2010 | China | Asian | Oral squamous cell carcinoma | 305/96 | Mixed | PB | PCR-RFLP | 0.71 |
| Hsiao PC | 2010 | China | Asian | Hepatocellular carcinoma | 102/347 | Mixed | HB | PCR-RFLP | 0.72 |
| Chen MK | 2009 | China | Asian | Oral cancer | 174/347 | Mixed | PB | PCR-RFLP | 0.72 |
| Naidu R | 2009 | Malaysia | Asian | Breast cancer | 410/275 | Female | PB | PCR-RFLP | 0.92 |
| Foley R | 2009 | Ireland | Caucasian | Prostate cancer | 95/196 | Male | PB | Sequencing | 0.62 |
| Konac E | 2009 | Turkey | Caucasian | Lung Cancer | 141/156 | Mixed | HB | PCR-RFLP | 0.34 |
| Li K | 2009 | China | Asian | Gastric Cancer | 87/106 | Mixed | PB | PCR | 0.51 |
| Munoz-Guerra MF | 2009 | Spain | Caucasian | Oral Cancer | 74/139 | Mixed | PB | PCR-RFLP | 0.01 |
| Kim HO | 2008 | Korea | Asian | Breast cancer | 90/102 | Female | PB | PCR | 0.64 |
| Jacobs EJ | 2008 | USA | Mixed | Prostate cancer | 1425/1453 | Male | PB | TaqMan | 0.04 |
| Apaydin I | 2008 | Turkey | Caucasian | Breast Cancer | 102/102 | Female | PB | PCR-RFLP | 0.42 |
| Lee JY | 2008 | Korea | Asian | Breast cancer | 1930/1677 | Female | PB | PCR-RFLP | 0.25 |
| Li H | 2007 | USA | Mixed | Prostate Cancer | 1072/1271 | Male | PB | PCR-RFLP | 0.16 |
| Konac E-O | 2007 | Turkey | Caucasian | Ovarian | 49/107 | Female | PB | PCR-RFLP | 0.23 |
| Konac E-C | 2007 | Turkey | Caucasian | Cervical | 32/107 | Female | PB | PCR-RFLP | 0.23 |
| Konac E-E | 2007 | Turkey | Caucasian | Endometrial | 21/107 | Female | PB | PCR-RFLP | 0.23 |
| Orr-Urtreger A | 2007 | Israel | Caucasian | Prostate Cancer | 402/300 | Male | PB | PCR-SSCP | 0.14 |
| Fransen K | 2006 | Sweden | Caucasian | Colorectal Cancer | 198/258 | Mixed | PB | PCR-RFLP | 0.92 |
| Ling TS | 2005 | China | Asian | Esophageal squamous cell carcinoma | 95/104 | Mixed | HB | PCR-RFLP | 0.57 |
| Chau CH | 2005 | USA | Mixed | Prostate cancer | 196/196 | Male | PB | Sequencing | 0.01 |
| Kuwai T | 2004 | Japan | Asian | Colorectal cancer | 100/100 | Mixed | PB | PCR-SSCP | 0.56 |
| Ollerenshaw M | 2004 | UK | Caucasian | Renal cell carcinoma | 160/288 | Mixed | PB | PCR-SSCP | 0 |
| Tanimoto K | 2003 | Japan | Asian | Head and neck squamous cell carcinoma | 55/110 | Mixed | PB | Sequencing | 0.55 |
| Clifford SC | 2001 | UK | Caucasian | Renal cell carcinoma | 35/143 | Mixed | HB | PCR-SSCP | 0.02 |
a Mixed means samples contain both female and male;
PB, public based; HB, hospital based; HWE, Hardy-Weinberg equilibrium; PCR, polymerase chain reaction; RFLP, restriction fragment length polymorphism; TaqMan, TaqMan SNP Genotyping Assays.
Figure 2T allele frequency of HIF-1α C1772T among control subjects stratified by ethnicity.
Associations between the C1772T polymorphism and cancer risk.
| Variables | TT+CT VS CC | TT VS CT +CC | TT VS CC | CT VS CC | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| OR(95%CI) |
|
| OR(95%CI) |
|
| OR(95%CI) |
|
| OR(95%CI) |
| |
| Overall | 36 |
| 0 | 26 |
| 0 | 25 |
| 0 | 36 | 1.16(0.97-1.38) | 0 |
| Overall for HWE | 28 |
| 0 | 17 |
| 0.01 | 17 |
| 0 | 28 |
| 0 |
| cancer cite | ||||||||||||
| Breast cancer | 6 | 1.12(0.87-1.52) | 0 | 5 | 1.64(0.56-4.77) | 0.11 | 5 | 1.69(0.56-5.14) | 0.09 | 6 | 1.10(0.83-1.46) | 0.16 |
| Cervical cancer | 3 | 1.81(0.79-4.10) | 0.01 | 2 |
| 0.24 | 2 |
| 0.16 | 3 | 1.47(0.79-2.74) | 0.29 |
| Colorectal cancer | 2 | 0.26(0.01-5.09) | 0.03 | 1 | 1.97(0.33-11.90) | 0 | 1 | 1.91(0.32-11.58) | 0 | 2 | 0.25(0.01-4.69) | 0 |
| Head and neck cancer | 5 | 1.20(0.87-1.67) | 0.48 | 4 |
| 0.79 | 3 |
| 0.72 | 5 | 1.03(0.69-1.62) | 0.92 |
| Lung cancer | 3 | 1.19(0.51-2.76) | 0 | 2 | 1.39(0.09-21.85) | 0.07 | 2 | 1.42(0.07-29.73) | 0.05 | 3 | 1.13(0.59-2.19) | 0.16 |
| Pancreatic cancer | 2 | 1.39(0.54 -3.56) | 0.03 | 1 |
| 0 | 1 |
| 0 | 2 | 0.51(0.02-11.53) | 0 |
| Prostate cancer | 6 | 1.36(0.95-1.96) | 0 | 5 | 1.31(0.54-3.18) | 0.01 | 5 | 1.34(0.54-3.30) | 0.01 | 6 | 1.34(0.93-1.92) | 0.03 |
| Renal cell carcinoma | 3 | 0.46(0.13-1.60) | 0.01 | 3 |
| 0.47 | 3 | 0.29(0.06-1.45) | 0.21 | 3 | 0.44(0.11-1.69) | 0.42 |
| Other cancer | 6 | 1.46(0.72-2.96) | 0 | 3 | 3.98(0.69-22.67) | 0.14 | 3 | 5.04(0.47-54.13) | 0.04 | 6 | 1.39(0.72-2.68) | 0.33 |
| Subgroup by ethnicity | ||||||||||||
| Caucasian | 15 | 1.13(0.78-1.65) | 0 | 13 |
| 0.01 | 13 | 1.78(0.80-3.94) | 0.95 | 15 | 0.98(0.65-1.48) | 0.01 |
| Asian | 18 |
| 0 | 9 |
| 0.97 | 9 |
| 0.95 | 18 |
| 0.01 |
| control source | ||||||||||||
| PB | 29 | 1.21(0.99-1.47) | 0 | 21 |
| 0 | 20 |
| 0 | 29 | 1.12(0.92-1.36) | 0.01 |
| HB | 7 | 1.33(0.87- 2.03) | 0.03 | 5 | 1.15(0.39-3.34) | 0.26 | 5 | 1.21(0.39-3.74) | 0.21 | 7 | 1.35(0.91-2.00) | 0.08 |
| Gender | ||||||||||||
| Female | 11 | 1.34(0.97-1.86) | 0 | 9 |
| 0.01 | 9 |
| 0 | 11 | 1.23(0.93-1.62) | 0.02 |
| Male | 6 | 1.36(0.95-1.96) | 0 | 5 | 1.31(0.54-3.18) | 0.01 | 5 | 1.34(0.54-3.30) | 0.01 | 6 | 1.34(0.93-1.92) | 0.03 |
a Number of comparisons.
b P value of Q-test for heterogeneity test.
c Fixed-effects model was used when P value for heterogeneity test≥0.05; Otherwise, Random-effects model was used.
d data after excluding those studies’ controls not in Hardy-Weinberg equilibrium.
Figure 3Forest plot of cancer risk associated with C1772T (TT +CT vs. CC). The squares and horizontal lines correspond to the OR and 95%CI. The area of the squares indicates the study-specific weight.
Figure 8Funnel Plot for Publication Bias of the C1772T Polymorphism.
Each point represents a separate study for the indicated association. Log (OR): natural logarithm of OR. Horizontal line: mean effect size.